Analyst Scoreboard: 19 Ratings For Edwards Lifesciences
Portfolio Pulse from Benzinga Insights
Edwards Lifesciences (NYSE:EW) received 19 analyst ratings over the past three months, with a mix of bullish and bearish perspectives. The average 12-month price target decreased by 15.39% to $83.32. Analysts have mostly lowered their price targets, reflecting cautious sentiment. Despite this, Edwards Lifesciences shows strong financial metrics, including a high net margin and low debt-to-equity ratio.
September 09, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Edwards Lifesciences has received mixed analyst ratings, with a notable decrease in the average 12-month price target by 15.39%. Analysts have predominantly lowered their price targets, indicating a cautious outlook. However, the company maintains strong financial health with a high net margin and low debt-to-equity ratio.
The decrease in the average price target and the predominance of lowered ratings suggest a negative short-term sentiment among analysts. This is likely to exert downward pressure on the stock price. However, the company's strong financial metrics, such as high net margin and low debt-to-equity ratio, provide a solid foundation, potentially mitigating some negative impacts.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100